Haemostatix (UK)

HaemostatsĀ are used by surgeons to manage problematic bleeding and to reduce time in the operating theatre during surgery. The products are applied in the form of sprays, gels or pads, and typically contain the enzyme thrombin, which promotes blood clotting, as the active ingredient. Haemostatix has developed a completely new class of haemostat based on a peptide that binds to the blood clotting protein, fibrinogen, instantly forming a clot. Haemostatix raised 3 rounds of financing in 2010 and 2011, in which Esperante participated, to advance the development of its lead haemostat product, Peprostat, which is currently in preclinical development. For more information, visitĀ www.haemostatix.com


Case Studies